Company Insights

ALKS customer relationships

Explore interactive graphBrowse insights index
ALKS customer relationship map

Alkermes’ customer footprint: concentrated wholesalers, enduring licenses, and manufacturing revenue

Alkermes plc operates as a hybrid biopharma: it commercializes its own CNS products in the U.S., manufactures products under contract for large pharma partners, and collects licensing and royalty revenue tied to technology and product rights. The company monetizes through (1) product sales of branded medicines such as VIVITROL, ARISTADA and LYBALVI; (2) manufacturing revenues from supply agreements (notably for RISPERDAL CONSTA); and (3) licensing/royalty income from technology and partner commercialization. These revenue streams create a mix of recurring royalties and higher-concentration wholesale revenue that drives both growth and counterparty risk. For a concise institutional briefing and deeper relationship analytics visit https://nullexposure.com/.

The commercial map investors need to know

Below are every customer and partner relationship identified in Alkermes’ FY2024 disclosures, presented with plain-English summaries and source notes.

  • Janssen Pharmaceuticals, Inc. — Alkermes details collaborative arrangements with Janssen related to long‑acting INVEGA products and RISPERDAL CONSTA, reflecting both licensing/technology transfer and manufacturing/supply activity. According to Alkermes’ FY2024 Form 10‑K, these arrangements underpin manufacturing revenue and historical milestone receipts. (Alkermes 10‑K, FY2024)

  • Cardinal Health Inc. — Cardinal is one of the three principal U.S. wholesalers Alkermes relies on for distribution of its marketed products. The 10‑K identifies Cardinal as a critical distribution partner for U.S. sales. (Alkermes 10‑K, FY2024)

  • Biogen International GmbH — Alkermes has collaborative arrangements with Biogen related to VUMERITY, indicating licensing or commercialization linkages that produce royalty or development-related revenue. (Alkermes 10‑K, FY2024)

  • Cencora, Inc. (formerly AmerisourceBergen / Cencora) — Cencora accounted for a material portion of VIVITROL gross sales (reported at ~16% of VIVITROL gross sales in FY2024), making it a major distribution counterparty. (Alkermes 10‑K, FY2024)

  • Janssen Pharmaceutica International — Listed separately in the filing, this international Janssen entity is identified in connection with the INVEGA products that were developed using Alkermes’ NanoCrystal technology. (Alkermes 10‑K, FY2024)

  • McKesson Corporation — McKesson represented the largest single buyer of VIVITROL in FY2024 (approximately 34% of VIVITROL gross sales), underscoring concentration risk in sales through major wholesalers. (Alkermes 10‑K, FY2024)

  • Cardinal Health (CAH) — The filing shows Cardinal not only as a sales channel but as a material receivable source across reporting periods, emphasizing its role in working capital and cash conversion. (Alkermes 10‑K, FY2024)

  • McKesson Corp (alternate listing) — Alkermes reiterates reliance on McKesson as one of the three largest U.S. wholesalers for distribution of marketed products. (Alkermes 10‑K, FY2024)

  • Cencora (COR) — The 10‑K also shows Cencora in receivables and revenue tables, confirming its status as a core wholesale counterparty that drives a nontrivial share of product sales and receivables. (Alkermes 10‑K, FY2024)

  • McKesson (CAKFF variant) — Multiple references to McKesson across schedules show it consistently represented a sizeable percentage of customer receivables and sales in the years shown. (Alkermes 10‑K, FY2024)

What the contract and relationship constraints reveal about the business

Alkermes’ disclosures reveal a distinct operating posture that investors should incorporate into valuation and risk workstreams:

  • Contracting posture: licensed and long‑dated arrangements. Alkermes executes exclusive licensing deals that include technology transfers and long‑running royalty structures (for example, know‑how royalties that reset annually and run up to 15 years from first commercial sale). These contracts create durable revenue lines and lock in counterparty commitments over time. (Alkermes 10‑K, FY2024)

  • Counterparty scale and concentration. The company bills large and very large enterprises — the three largest U.S. wholesalers (McKesson, Cardinal, Cencora) dominate distribution and accounted for a combined material share of VIVITROL sales. This produces high counterparty concentration that compresses risk diversification but simplifies commercial execution. (Alkermes 10‑K, FY2024)

  • Criticality and commercial dependence. Licensing relationships are critical to product commercialization and to royalty/manufacturing revenue; manufacturing agreements for third parties are significant to reported manufacturing revenues. These arrangements are active and operationally important today. (Alkermes 10‑K, FY2024)

  • Geography and go‑to‑market focus. Alkermes’ revenue base is heavily U.S.‑centric; the U.S. represents the overwhelming majority of revenues by customer location, concentrating regulatory and commercial risk in North America. (Alkermes 10‑K, FY2024)

  • Role mix: seller, licensor, manufacturer, distributor relationships. Alkermes functions as a seller of its own products, licensor of technology, manufacturer for partners and supplier to wholesalers — a multi‑role structure that diversifies revenue types but increases contractual complexity. (Alkermes 10‑K, FY2024)

If you want a sector‑level breakdown or counterparty scoring model built from these relationship signals, start here: https://nullexposure.com/.

Investment implications — upside drivers and risk vectors

  • Upside: Long‑dated licensing terms and ongoing manufacturing agreements create steady royalty and manufacturing revenue that are relatively predictable once scale is established. Alkermes reported trailing revenue of roughly $1.48 billion and EBITDA of $281.1 million, demonstrating positive operating leverage in its current mix. (Company filings, trailing twelve months)

  • Risks: High customer concentration in three wholesalers amplifies single‑point counterparty risk—McKesson alone represented roughly a third of VIVITROL gross sales in FY2024. Manufacturing for third parties (e.g., Janssen/RISPERDAL CONSTA) creates operational dependency on partner approvals and supply agreements. The U.S. revenue concentration and material reliance on licensees for commercialization are additional strategic constraints. (Alkermes 10‑K, FY2024)

  • Operational maturity: The presence of executed long‑term license terms and multi‑year royalty resets signals a mature commercialization posture for certain assets, while ongoing reliance on partner commercialization for other products indicates continued execution risk on growth. (Alkermes 10‑K, FY2024)

Bottom line and recommended next steps for investors

  • Key takeaways: Alkermes combines branded product sales, contract manufacturing and licensing revenue into a coherent commercial model; wholesale concentration and a few large licensing/manufacturing partners are the defining risk/return levers. Investors should weight counterparty concentration and license duration when modeling cash flow durability and downside scenarios.

  • Actionable items: Review cash conversion schedules tied to Cardinal/McKesson/Cencora receivables, stress test royalty/mfg revenue under partner disruption scenarios, and incorporate U.S. geographic concentration into downside cases.

For more structured counterparty scoring and relationship analytics tailored to portfolio use, visit https://nullexposure.com/. For a custom brief or to commission a counterparty risk memo on Alkermes, contact the team through our site: https://nullexposure.com/.

Sources: Alkermes plc Form 10‑K for the year ended December 31, 2024 (company disclosures cited throughout).